Recombinant Fusion Proteins
"Recombinant Fusion Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes.
| Descriptor ID |
D011993
|
| MeSH Number(s) |
D12.776.828.300
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Recombinant Fusion Proteins".
Below are MeSH descriptors whose meaning is more specific than "Recombinant Fusion Proteins".
This graph shows the total number of publications written about "Recombinant Fusion Proteins" by people in this website by year, and whether "Recombinant Fusion Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 3 | 20 | 23 |
| 1997 | 4 | 18 | 22 |
| 1998 | 2 | 18 | 20 |
| 1999 | 3 | 16 | 19 |
| 2000 | 6 | 26 | 32 |
| 2001 | 2 | 18 | 20 |
| 2002 | 3 | 37 | 40 |
| 2003 | 9 | 23 | 32 |
| 2004 | 5 | 20 | 25 |
| 2005 | 4 | 23 | 27 |
| 2006 | 2 | 17 | 19 |
| 2007 | 3 | 16 | 19 |
| 2008 | 3 | 12 | 15 |
| 2009 | 6 | 9 | 15 |
| 2010 | 0 | 13 | 13 |
| 2011 | 6 | 10 | 16 |
| 2012 | 3 | 9 | 12 |
| 2013 | 4 | 6 | 10 |
| 2014 | 3 | 3 | 6 |
| 2015 | 1 | 7 | 8 |
| 2016 | 2 | 7 | 9 |
| 2017 | 2 | 3 | 5 |
| 2018 | 2 | 5 | 7 |
| 2019 | 2 | 2 | 4 |
| 2020 | 2 | 4 | 6 |
| 2021 | 1 | 0 | 1 |
| 2023 | 0 | 1 | 1 |
| 2024 | 1 | 0 | 1 |
| 2025 | 2 | 2 | 4 |
| 2026 | 1 | 3 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Recombinant Fusion Proteins" by people in Profiles.
-
Comparison of Specific Glucagon-Like Peptide-1 Receptor Agonists on Kidney Outcomes Among Patients With Type 2 Diabetes. Am J Kidney Dis. 2026 Sep; 88(3):366-377.
-
Sotatercept reduces bone morphogenetic protein signaling in patients with pulmonary arterial hypertension. Sci Transl Med. 2026 May 20; 18(850):eads5175.
-
Endogenous GIP signaling is indispensable for DPP-4 inhibitor-mediated metabolic control in mice. J Diabetes Investig. 2026 Apr; 17(4):567-575.
-
Effects of glucagon-like peptide-1 receptor agonists on male reproductive hormones, semen parameters, and metabolic outcomes: a systematic review. J Sex Med. 2026 Jan 07; 23(2).
-
Comparative effectiveness of GLP-1 receptor agonists on cardiovascular outcomes among adults with type 2 diabetes and moderate cardiovascular risk: emulation of a target trial. Diabetes Res Clin Pract. 2025 Nov; 229:112910.
-
Risk of Sight-Threatening Diabetic Retinopathy with Glucagon-Like Peptide-1 Receptor Agonist Use in Routine Clinical Practice: Comparative Effectiveness of Semaglutide, Dulaglutide, Liraglutide, and Exenatide. Ophthalmol Retina. 2026 Feb; 10(2):142-151.
-
Activity-attenuated serum albumin-fused interleukin-33 suppresses experimental autoimmune encephalomyelitis. Cell Rep Med. 2025 Jul 15; 6(7):102231.
-
Splicing of erythroid transcription factor is associated with therapeutic response in myelodysplastic syndromes. J Clin Invest. 2025 Jul 01; 135(13).
-
Anti-VEGF Pharmaceutical Prior Authorization in Retina Practices. JAMA Ophthalmol. 2024 08 01; 142(8):716-721.
-
Comparison of the efficacy and safety of SCD411 and reference aflibercept in patients with neovascular age-related macular degeneration. Sci Rep. 2024 06 26; 14(1):14752.